Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli . This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.
1. A pharmaceutical composition comprising phosphorylated hexaacyl disaccharide (PHAD) and a buffer selected from the group consisting of citrate and succinate from 25 mM to about 50 mM.
2. The composition of claim 1 , wherein the composition comprises phosphatidylcholine at a molar ratio with PHAD at about 1:1 to about 20:1, wherein phosphatidylcholine is selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).
3. The composition of claim 1 , wherein the buffer concentration is from 30 mM to about 50 mM.
4. The composition of claim 1 , wherein the buffer concentration is from 40 mM to about 50 mM, and is at a pH of about 4.0 to about 7.5.
5. The composition of claim 1 , wherein the buffer is citrate.
6. The composition of claim 1 , wherein the buffer is succinate.
7. The composition of claim 1 , wherein the composition is stable when exposed to room temperature for 60 or more days.
8. The composition of claim 1 , wherein the composition is stable when stored at room temperature for 6 or more months and between room temperature and about 37° C. for 2 or more months.
9. The composition of claim 1 , wherein the composition is substantially free of saline.
10. The composition of claim 1 , wherein the composition contains less than 10 mM of NaCl.
11. The composition of claim 1 , wherein the composition is essentially free of NaCl.
12. The composition of claim 1 , wherein the composition is essentially free of cholesterol, phosphatidylglycerol, and squalene.
13. The composition of claim 1 , wherein the composition comprises an effective amount of FimCH.
14. The composition of claim 1 , wherein the composition has not been subjected to lyophilization.
15. A pharmaceutical composition comprising phosphorylated hexaacyl disaccharide (PHAD) and a buffer selected from the group consisting of sodium phosphate dibasic, sodium phosphate monobasic, potassium phosphate monobasic, and potassium phosphate dibasic from 28 mM to about 50 mM, wherein said composition is substantially free of saline.
16. The composition of claim 15 , wherein the composition comprises a phosphatidylcholine at a molar ratio with PHAD at about 1:1 to about 20:1, wherein phosphatidylcholine is selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).
17. The composition of claim 15 , wherein the buffer concentration is from 30 mM to about 50 mM.
18. The composition of claim 15 , wherein the buffer concentration is from 40 mM to about 50 mM, at a pH of about 4.0 to about 7.5.
19. The composition of claim 15 , wherein the composition contains less than 10 mM of NaCl.
20. The composition of claim 15 , wherein the composition is essentially free of NaCl.
21. The composition of claim 15 , wherein the composition is essentially free of cholesterol, phosphatidylglycerol, and squalene.
22. The composition of claim 15 , wherein the composition comprises an effective amount of FimCH.
23. The composition of claim 15 , wherein the composition is stable when exposed to room temperature for 60 or more days.
24. The composition of claim 15 , wherein the composition is stable when exposed to room temperature for 6 or more months and between room temperature and about 37° C. for 2 or more months.
25. The composition of claim 15 , wherein the composition has not been subjected to lyophilization.
26. A method for administering a vaccine composition to a human comprising the step of:
administering to the human a vaccine composition comprising an adjuvant formulation containing phosphorylated hexaacyl disaccharide (PHAD), and a buffer selected from the group consisting of citrate and succinate from 25 mM to about 50 mM.
27. The method of claim 26 , wherein the adjuvant formulation is essentially free of cholesterol and phosphatidylglycerol.
28. A method for treating recurrent urinary tract infections in a human comprising the step of:
administering to the human a vaccine composition comprising (i) an effective amount of FimCH, (ii) an adjuvant formulation containing PHAD, and a buffer selected from the group consisting of citrate and succinate from 10 mM to about 50 mM, wherein the composition is essentially free of squalene.
29. The method of claim 28 , wherein the composition is substantially free of saline.
30. The method of claim 28 , wherein the buffer is selected from the group of citrate and succinate from 25 mM to about 50 mM, at a pH of about 4.0 to about 7.5.